
In this closing segment, faculty distill the practical philosophy that runs through the program: a center-based start with a deliberate, clearly communicated transition remains the right approach for most patients.

In this closing segment, faculty distill the practical philosophy that runs through the program: a center-based start with a deliberate, clearly communicated transition remains the right approach for most patients.

This segment compares the practical experience of delivering therapy across the center, local oncology, and home, and considers which patients are best suited to each.

This segment examines the burdens that persist even within a well-designed transition pathway.

This segment explores who owns each part of the transition and how teams keep patients safe once care moves closer to home.

This segment centers on a distinction faculty return to throughout: transitioning care is not transferring management.

This segment addresses the discomfort of moving infusion care off the trial model, where axatilimab was delivered at academic centers.

This segment walks through the practical mechanics of delivering infusion-based therapy in chronic GVHD, using axatilimab as the model.

This segment brings the approved therapies side by side and asks what actually drives treatment selection.

This segment offers a focused look at axatilimab, the first and only CSF1R-directed monoclonal antibody approved for chronic GVHD.

ROCKSTAR data and real-world experience position belimumab as a convenient, well-tolerated option for steroid-refractory chronic GVHD, while ibrutinib use declines.

Explore 2026 steroid-refractory chronic GVHD care: four FDA-approved drugs, key trial results, and how ECP fits into real-world treatment selection.

Explore 2026 options for steroid-refractory chronic GVHD: four FDA-approved agents, key trial evidence, and where ECP fits in care.

Experts detail how steroid-refractory chronic GVHD care now uses targeted therapies and personalized choices, weighing organs, side effects, and infusion logistics.

Hana Safah, MD, and Corey Cutler, MD, MPH, conclude with clinical insights on addressing medication access and the supportive care needs of patients with GvHD.

Drs Cutler and Safah look to the future of chronic GvHD treatment and discuss ongoing research, highlighting studies investigating axatilimab and abatacept.

Hematologist-oncologists give an overview of the 3 approved treatment options for patients with steroid-refractory chronic GvHD—ruxolitinib, ibrutinib, and belumosudil—and highlight the REACH3 and ROCKstar studies.

Drs Safah and Cutler discuss treatment practices for patients with steroid-refractory graft-vs-host disease and highlight patients who are steroid dependent.

Hematologist-oncologists discuss the first-line treatment options for patients with chronic GvHD and the advantages and disadvantages of steroids.

Hana Safah, MD, reviews the NIH staging system for graft-vs-host disease and discusses the importance of staging in determining prognosis and informing treatment decisions.

Corey Cutler, MD, MPH, discusses the role of prognostic markers in graft-vs-host disease and how they can potentially inform treatment selection.

Hematologist-oncologists Corey Cutler, MD, MPH, and Hana Safah, MD, discuss how graft-vs-host disease presents and the importance of early intervention.

Experts on graft-vs-host disease (GvHD) introduce themselves and provide an overview of GvHD, highlighting diagnosis, symptoms, risk stratification, and prevention.

The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.

The panel takes a look at the possible re-approval of belantamab as a treatment for multiple myeloma in the future.

Sagar Lonial, MD, starts a conversation on infection and hypogamma prevention in patients receiving CAR-T therapy for multiple myeloma.

Noopur Raje, MD, muses on how to manage CRS and ICANS in patients being treated for multiple myeloma, and how serious these conditions truly are.

Dr Hana Safah continues the discussion on novel targets in multiple myeloma with a look at FcRH5 and data on cevostamab.

Amrita Krishnan, MD, discusses targeting GPRC5D in multiple myeloma, and where it fits in the treatment sequence.

Krina Patel, MD, reviews recent data from the MAJESTIC studies on immunotherapy combination treatments in R/R MM.

Amrita Krishnan, MD, details how she approaches retreating a patient with R/R MM with a BCMA-targeting bispecific agent.

February 20th 2023

February 6th 2023

January 30th 2023

February 20th 2023